ArticleNature medicine2020
Peripheral CD8
2 registry-linked trialsOpen access · greenAbstract read
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 239 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
239citing papers in PubMed, 2 pooled it
18.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Who cites it
239 citing papers in PubMed, 2 syntheses or guidelines pooled it, 364 citations in OpenAlex.
- Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy.Cell genomics · 2025Pooled it
- Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis.Immunotherapy · 2021Pooled it
- T-Cell Receptor and Immune Gene Expression Pharmacodynamics for Durvalumab Alone and with Tremelimumab or Bevacizumab in Unresectable Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma.Journal for immunotherapy of cancer · 2025Trial
- Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer.Journal for immunotherapy of cancer · 2025Trial
- TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study.International journal of cancer · 2025Trial
- Coupling of response biomarkers between tumor and peripheral blood in patients undergoing chemoimmunotherapy.Cell reports. Medicine · 2025Trial
- Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity.Nature communications · 2021Trial
- Greater extent of blood-tumor TCR repertoire overlap is associated with favorable clinical responses to PD-1 blockade.Cancer science · 2021Trial
- Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.International journal of molecular sciences · 2021Trial
- Inhibitory receptor profiles for joint prediction of benefit and toxicity in immune checkpoint blockade.iScience · 2026Review
- Towards liquid biopsy-based analysis of antitumour immunity.Nature reviews. Clinical oncology · 2026Review
- Anti-CMV IgG titer determines organ-specific protection toward immune checkpoint blockade-induced toxicities.Journal for immunotherapy of cancer · 2026Article
- Exploring the functions of NKG7 in CD4+ and CD8+ T cells during malaria.PLoS pathogens · 2026Article
- Circulating B cell and T cell activation states predict clinical outcomes in melanoma and reveal dynamic immune reinvigoration with checkpoint inhibitor immunotherapy.Journal for immunotherapy of cancer · 2026Article
- Engineered Bacterial Membranes as Next-Generation Platforms for Cancer Immunotherapy.Small science · 2026Review
- Longitudinal single-cell and TCR repertoire profiling characterizes clonal entrapment in patients with pMMR/MSS locally advanced rectal cancer.Cell discovery · 2026Article
- Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance.Nature communications · 2026Article
- Tumor-Induced Splenic Remodeling: Mechanisms of Systemic Immunosuppression and Emerging Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Dynamic systemic immune-inflammation index predicts survival after neoadjuvant immunotherapy in gastric cancer: A multicenter study.iScience · 2026Article
179 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 4 institutions in 1 country.
Benjamin P FairfaxMRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. benjamin.fairfax@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0001-7413-5002
Chelsea A TaylorMRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Robert A WatsonMRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Isar NassiriMRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Sara DanielliDepartment of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Hai FangWellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-3961-8572
Elise A MahéMRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Rosalin CooperMRC-Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Victoria WoodcockDepartment of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID http://orcid.org/0000-0001-7656-728X
Zoe TraillDepartment of Radiology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
M Hussein Al-MossawiBotnar Research Centre, NDORMS, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2312-3754
Julian C KnightNIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID http://orcid.org/0000-0002-0377-5536
Paul KlenermanNIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Miranda PayneDepartment of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Mark R MiddletonDepartment of Oncology, University of Oxford & Oxford Cancer Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID http://orcid.org/0000-0003-0167-1685
Churchill Hospital · GBCentre for Human Genetics · GBJohn Radcliffe Hospital · GBUniversity of Oxford · GB
Funding
Cancer Research UK A19716Cancer Research UK (CRUK) C2195/A19716Cancer Research UK (CRUK) C64881/A26189Wellcome Trust 109965Wellcome Trust 109965/Z/15/ZWellcome Trust 201488Wellcome Trust 201488/Z/16/ZWellcome Trust 204969Wellcome Trust (Wellcome) [201488/Z/16/Z]Wellcome Trust (Wellcome) WT109965MA
Abstract
Immune checkpoint blockade (ICB) of PD-1 and CTLA-4 to treat metastatic melanoma (MM) has variable therapeutic benefit. To explore this in peripheral samples, we characterized CD8
Indexed as
AdultAntibodiesAntigens, Differentiation, T-LymphocyteCD8-Positive T-LymphocytesCell ProliferationChemokine CCL4Cohort StudiesCTLA-4 AntigenFemaleGene Expression ProfilingHumansImmune SystemImmunotherapyMaleMelanomaMembrane ProteinsAntibodiesAntigens, Differentiation, T-LymphocyteCCL4 protein, humanChemokine CCL4CTLA-4 AntigenCTLA4 protein, humanGNLY protein, humanMembrane ProteinsNKG7 protein, humanPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT05236114ClinicalTrials.gov
NCT06163534ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.